Identifying glycan biomarkers for cholangiocarcinoma
Official title: Glycan Biomarkers for Cholangiocarcinoma
Funded at Medical University of South Carolina · NIH-11049609 · Data updated 2026-11-12
This study is looking at how certain changes in sugars found in blood and tissue can help doctors spot bile duct cancer earlier and tell it apart from other illnesses, with the hope of improving diagnosis and treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | December 5, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $671,384 |
| NIH project number | 1R01CA289381-01A1 |
| Project ID | NIH-11049609 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for cholangiocarcinoma or those presenting with symptoms suggestive of biliary cancer.
✕Less likely to help
Patients with other types of cancers unrelated to biliary structures may not benefit from this research.
What this research studies
This research focuses on cholangiocarcinoma, a lethal cancer affecting the bile ducts. It aims to identify specific glycan changes in tissue and serum that could serve as biomarkers for early detection and differentiation from other diseases. By analyzing these glycan alterations, the research seeks to improve diagnostic accuracy and potentially enhance treatment outcomes for patients. The approach involves studying both serum and tissue samples to establish a reliable biomarker panel.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnosis of cholangiocarcinoma, improving patient outcomes.
How similar studies have gone: Previous research has shown promise in using glycan biomarkers for cancer detection, suggesting potential success for this approach.
Where this research is happening
-
Medical University of South Carolina
Charleston, United States Active
Researchers
- Principal investigator: Mehta, Anand S. — Medical University of South Carolina
- Study coordinator: Mehta, Anand S.
Related research
Other NIH-funded projects on the same topics.
-
A new mouse model to study intrahepatic cholangiocarcinoma and its immunotherapy
A new mouse model helps researchers understand intrahepatic cholangiocarcinoma and test immune-based treatments to improve outcomes.
-
Radiation plus a patient’s own immune cells to boost cholangiocarcinoma treatment
This project tests a therapy that combines precise radiation and the patient’s own dendritic cells with immune drugs to help fight intrahepatic cholangiocarcinoma in people who cannot have surgery.
-
Worldwide genetics of bile duct (cholangiocarcinoma)
Researchers are looking for genetic patterns that raise the risk of bile duct cancer in people from diverse regions worldwide.
-
MKK4 and Liver Regeneration after Major Liver Surgery
A study at Mayo Clinic will test a new drug, HRX215, to help people regrow liver tissue after major liver surgery for cancer.
-
New mouse model to improve immune therapy for intrahepatic bile duct (cholangiocarcinoma) cancer
This project builds a new mouse model to help make immune-based treatments work better for people with intrahepatic cholangiocarcinoma, a type of bile duct liver cancer.
-
Mutant IDH in bile duct cancer and its impact on immune response
A patient-facing look at how mutations in IDH1 drive bile duct cancer and how targeting this mutation could help immune cells fight the tumor.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.